An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease.

Trial Profile

An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Siltuximab (Primary)
  • Indications Giant lymph node hyperplasia
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 02 Aug 2017 This trial has been completed in Germany (on-2017-03-01) as per European Clinical Trials Database record.
    • 03 Apr 2017 This trial has been completed in Belgium as per European Clinical Trials Database record.
    • 19 Mar 2017 This trial has been completed in Spain as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top